Multimodal therapy is feasible in elderly anal cancer patients

References

• Bentzen AG, Guren MG, Wanderas EH, et al. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. Int J Radiat Oncol Biol Phys 2012;83:e173–80.
   PubMed Web of Science ®Google Scholar
• Clark MA, Hartley A, Geh JI. Cancer of the anal canal. Lancet Oncol 2004;5:149–57.
   PubMed Web of Science ®Google Scholar
• Lund JA, Wibe A, Sundstrom SH, et al. Anal carcinoma in mid-Norway 1970-2000. Acta Oncol 2007;46:1019–26.
   PubMed Web of Science ®Google Scholar
• Papillon J, Mayer M, Montbarbon JF, et al. A new approach to the management of epidermoid carcinoma of the anal canal. Cancer 1983;51:1830–7.
   PubMed Web of Science ®Google Scholar
• Cummings BJ. The place of radiation therapy in the treatment of carcinoma of the anal canal. Cancer Treat Rev 1982;9:125–47.
   PubMed Web of Science ®Google Scholar
• Cummings BJ. Carcinoma of the anal canal–radiation or radiation plus chemotherapy? Int J Radiat Oncol Biol Phys 1983;9:1417–18.
   PubMed Web of Science ®Google Scholar
• Flam MS, John M, Lovalvo LJ, et al. Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases. Cancer 1983;51:1378–87.
   PubMed Web of Science ®Google Scholar
• Nigro ND, Seydel HG, Considine B, et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 1983;51:1826–9.
   PubMed Web of Science ®Google Scholar
• Leon O, Guren M, Hagberg O, et al. Anal carcinoma: survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiother Oncol 2014;113:352–8.
   PubMed Web of Science ®Google Scholar
• Benson AB, 3rd., Arnoletti JP, Bekaii-Saab T, et al. Anal carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:449–54.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Northover JM, Cervantes A. Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v87–92.
   Google Scholar
• Lestrade L, De Bari B, Montbarbon X, et al. Radiochemotherapy and brachytherapy could be the standard treatment for anal canal cancer in elderly patients? A retrospective single-center analysis. Med Oncol 2013;30:402.
   PubMed Web of Science ®Google Scholar
• Allal AS, Obradovic M, Laurencet F, et al. Treatment of anal carcinoma in the elderly: feasibility and outcome of radical radiotherapy with or without concomitant chemotherapy. Cancer 1999;85:26–31.
   PubMed Web of Science ®Google Scholar
• Charnley N, Choudhury A, Chesser P, et al. Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. Br J Cancer 2005;92:1221–5.
   PubMed Web of Science ®Google Scholar
• Chauveinc L, Buthaud X, Falcou MC, et al. Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy. Br J Cancer 2003;89:2057–61.
   PubMed Web of Science ®Google Scholar
• Claren A, Doyen J, Falk AT, et al. Results of age-dependent anal canal cancer treatment: a single centre retrospective study. Dig Liver Dis 2014;46:460–4.
   PubMedGoogle Scholar
• De Bari B, Lestrade L, Chekrine T, et al. Should the treatment of anal carcinoma be adapted in the elderly? A retrospective analysis of acute toxicities in a French center and a review of the literature. Cancer Radiother 2012;16:52–7.
   PubMed Web of Science ®Google Scholar
• Fallai C, Cerrotta A, Valvo F, et al. Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol 2007;61:261–8.
   PubMed Web of Science ®Google Scholar
• Foo M, Link E, Leong T, et al. Impact of advancing age on treatment and outcomes in anal cancer. Acta Oncol 2014;53:909–16.
   PubMed Web of Science ®Google Scholar
• Saarilahti K, Arponen P, Vaalavirta L, et al. Chemoradiotherapy of anal cancer is feasible in elderly patients: treatment results of mitomycin-5-FU combined with radiotherapy at Helsinki University Central Hospital 1992-2003. Acta Oncol 2006;45:736–42.
   PubMed Web of Science ®Google Scholar
• Valentini V, Morganti AG, Luzi S, et al. Is chemoradiation feasible in elderly patients? A study of 17 patients with anorectal carcinoma. Cancer 1997;80:1387–92.
   PubMed Web of Science ®Google Scholar
• Hermanek P, Sobin LH. TNM classification of malignant tumors. 4th ed. Berlin, New York: Springer-Verlag; 1987.
   Google Scholar
• Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J 2009;9:265–90.
   Web of Science ®Google Scholar
• Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012;30:4344–51.
   PubMed Web of Science ®Google Scholar
• Peiffert D, Tournier-Rangeard L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012;30:1941–8.
   PubMed Web of Science ®Google Scholar
• Skyrud KD, Bray F, Moller B. A comparison of relative and cause-specific survival by cancer site, age and time since diagnosis. Int J Cancer 2014;135:196–203.
   PubMed Web of Science ®Google Scholar
• Sunesen KG, Norgaard M, Lundby L, et al. Cause-specific colostomy rates after radiotherapy for anal cancer: a Danish multicentre cohort study. J Clin Oncol 2011;29:3535–40.
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012;30:1829–34.
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Jonker JM, de Rooij SE, et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 2012;13:e437–44.
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Vos AG, Smorenburg CH, et al. The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. Oncologist 2012;17:1439–49.
   PubMed Web of Science ®Google Scholar
• Julie DR, Goodman KA. Advances in the management of anal cancer. Curr Oncol Rep 2016;18:20.
   PubMed Web of Science ®Google Scholar
• Bentzen AG, Balteskard L, Wanderås EH, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol 2013;52:736–44.
   PubMed Web of Science ®Google Scholar
• Julie KA, Oh JH, Apte AP, et al. Predictors of acute toxiciries during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. Acta Oncol 2016;55:208–16.
   PubMed Web of Science ®Google Scholar
• De Bari B, Jumeau R, Bouchaab H, et al. Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients. Acta Oncol 2016;55:767–73.
   PubMed Web of Science ®Google Scholar
• Tomasoa NB, Meulendijks D, Nijkamp J, et al. Clinical outcome in patients treated with simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal. Acta Oncol 2016;55:760–6.
   PubMed Web of Science ®Google Scholar
• Ojerholm E, Kirk ML, Thompson RF, et al. Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy. Acta Oncol 2015;54:1209–17.
   PubMed Web of Science ®Google Scholar